Peer-Reviewed Publications

    Assessment of cigarette smoking in epidemiologic studies

    Weitkunat, R.; Coggins, C. R. E.; Sponsiello-Wang, Z.; Kallischnigg, G.; Dempsey, R.
    Published
    Sep 1, 2013
    DOI
    10.2478/cttr-2013-0940
    Link to publication
    Topic
    Summary

    The assessment of cumulative exposure based on collecting information on the history of active cigarette smoking has been and is being undertaken in a variety of ways. While a very detailed assessment may be required for studies with a focus on particular aspects of smoking behavior and history, comparability of measurements and results across studies remains a primary concern. Addressing the problem of heterogeneity of exposure assessment across studies can be achieved by a core set of questions that cover the major dimensions of cigarette smoking, and yet comply with current criteria used for defining smoking history and status. In studies where no very high level of exposure assessment is required or where smoking is not the major subject of investigation, a practical standardized core set of questions appears to be of considerable value, in particular with regard to making results more comparable across studies.

    Related Publications

    Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

    Clinical

    Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

    Clinical

    Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

    Clinical

    Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

    Clinical

    Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

    Clinical

    Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

    Clinical

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.